Intelligence Profile
Safety Profile
Safety Profile of Elamipretide (SS-31)
Evidence Limitations: The safety data for elamipretide is currently limited, with most available evidence coming from preclinical animal studies and one completed Phase 1/2 trial. Comprehensive human safety data remains thin, and this assessment should be considered preliminary.
Known Side Effects
Based on the available evidence, specific side effect profiles from human studies are not well-documented in the provided research. The completed Phase 1/2 trial in Friedreich's ataxia patients (NCT05168774) would contain relevant safety data, but detailed results are not included in the evidence provided.
Contraindications
No specific contraindications have been established based on the available evidence. This represents a significant gap in the current safety profile.
Drug Interactions
The evidence does not provide information about drug-drug interactions with elamipretide. One study examined combination therapy with nicotinamide mononucleotide (NMN), suggesting potential for combination approaches, but formal interaction studies are not documented in the available literature.
Special Populations
Evidence is particularly thin regarding safety in special populations, including:
- Pregnant or breastfeeding women
- Pediatric patients
- Elderly patients
- Patients with severe hepatic or renal impairment
- Patients with cardiovascular disease
Preclinical Safety Observations
Animal studies suggest elamipretide may be generally well-tolerated, as evidenced by its use across multiple organ systems (brain, heart, liver, spinal cord) in research models. However, these preclinical findings cannot be directly extrapolated to human safety.
Clinical Considerations
Given the limited human safety data, elamipretide should only be used under appropriate clinical supervision and regulatory oversight. Healthcare providers should exercise particular caution when considering its use, especially in vulnerable populations.
Disclaimer: This safety information is based on limited available evidence and should not replace consultation with healthcare professionals. Patients should not use this compound outside of approved clinical trials or medical supervision.
Key Gap: Comprehensive Phase 3 safety data and post-market surveillance information are not available, representing a significant limitation in establishing a complete safety profile for elamipretide.